A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072

* Chronic hepatitis C virus (HCV), genotype 1 infection (HCV ribonucleic acid level greater than or equal to 100,000 IU/mL) at screening * Liver biopsy within 3 years with histology consistent with HCV-induced liver damage, with no evidence of cirrhosis or liver pathology due to any cause other than chronic HCV * Treatment naïve male or female between the ages of 18 and 65 * Females must be post-menopausal for more than 2 years or surgically sterile * Negative screen for drugs and alcohol * Negative hepatitis B surface antigen (HBsAg) and anti-human immunodeficiency virus antibodies (anti-HIV Ab) * No use of cytochrome P450 3A (CYP3A) and cytochrome P450 2C8 (CYP2C8) enzyme inducers or inhibitors within 1 month of dosing * Be in a condition of general good health, as perceived by the investigator, other than HCV infection

* Significant sensitivity to any drug * Use of herbal supplements within 2 weeks prior to study drug dosing * History of major depression within 2 years * Prior treatment with any investigational or commercially available anti-HCV agents * Abnormal laboratory tests